213 related articles for article (PubMed ID: 3335000)
1. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Andrews PA; Velury S; Mann SC; Howell SB
Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
[TBL] [Abstract][Full Text] [Related]
2. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
3. Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells.
Andrews PA; Mann SC; Huynh HH; Albright KD
Cancer Res; 1991 Jul; 51(14):3677-81. PubMed ID: 1648442
[TBL] [Abstract][Full Text] [Related]
4. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
5. Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
Mann SC; Andrews PA; Howell SB
Anticancer Res; 1988; 8(6):1211-5. PubMed ID: 3218956
[TBL] [Abstract][Full Text] [Related]
6. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.
Andrews PA; Albright KD
Cancer Res; 1992 Apr; 52(7):1895-901. PubMed ID: 1551118
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
Naredi P; Heath DD; Enns RE; Howell SB
Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells.
Marverti G; Andrews PA
Clin Cancer Res; 1996 Jun; 2(6):991-9. PubMed ID: 9816260
[TBL] [Abstract][Full Text] [Related]
10. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
Teicher BA; Holden SA; Kelley MJ; Shea TC; Cucchi CA; Rosowsky A; Henner WD; Frei E
Cancer Res; 1987 Jan; 47(2):388-93. PubMed ID: 3539321
[TBL] [Abstract][Full Text] [Related]
12. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
[TBL] [Abstract][Full Text] [Related]
13. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.
Waud WR
Cancer Res; 1987 Dec; 47(24 Pt 1):6549-55. PubMed ID: 3677093
[TBL] [Abstract][Full Text] [Related]
14. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
Jekunen A; Vick J; Sanga R; Chan TC; Howell SB
Cancer Res; 1992 Jul; 52(13):3566-71. PubMed ID: 1617625
[TBL] [Abstract][Full Text] [Related]
15. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
Zinkewich-Péotti K; Andrews PA
Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
[TBL] [Abstract][Full Text] [Related]
16. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
17. [Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance].
Zhou Y; Chen H; Yang Q
Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):680-3. PubMed ID: 9275551
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
Chau Q; Stewart DJ
Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
[TBL] [Abstract][Full Text] [Related]
20. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.
McLaughlin K; Stephens I; McMahon N; Brown R
Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
